The short version of growth hormone fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-10 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
The cycle is present in microorganisms that cause disease but is absent in mammals, for example humans. There is a strong plausibility of the development of antibiotics that would attack the glyoxylate cycle, which would kill the disease-causing microorganisms that depend on the cycle for their survival, yet would not harm humans where the cycle, and thus the enzymes that the antibiotic would target, are absent.
The colonization of Tahiti occurred in a time of rivalry for resources of the Pacific by colonizing European nations including the French and the British. It was also a time of rivalry and fighting between the people of Tahiti and neighbouring islands. It is unclear which is the first European ship to arrive at the island of Tahiti but it is often recognised as being HMS Dolphin captained by British Captain Samuel Wallis on 18 June 1767. He met a welcoming party of Tahitians who traded with him. Cultural differences leading to grave communication errors that resulted in a battle in Matavai Bay between three hundred war canoes and HMS Dolphin which fired on the war canoes with muskets, quarterdeck guns and then cannons. The Tahitian chief Obera (Purea) ordered peace offerings from her people after this battle and Wallis and the Tahitians departed on amicable terms when he left on 27 July 1767. A few months later the French arrived on 2 April 1768 with the ships Boudeuse and Etoile captained by Louis-Antoine de Bougainville.
== Further reading == Krentz, Benjamin D.; Mulheron, Heidi J.; Semrau, Jeremy D.; DiSpirito, Alan A.; Bandow, Nathan L.; Haft, Daniel H.; Vuilleumier, Stéphane; Murrell, J. Colin; McEllistrem, Marcus T.; Hartsel, Scott C.; Gallagher, Warren H. (30 November 2010). "A Comparison of Methanobactins from Methylosinus trichosporium OB3b and Methylocystis Strain SB2 Predicts Methanobactins Are Synthesized from Diverse Peptide Precursors Modified To Create a Common Core for Binding and Reducing Copper Ions". Biochemistry. 49 (47): 10117–10130. doi:10.1021/bi1014375. PMC 3924600. PMID 20961038. Dalton, edited by J. Colin Murrell, Howard (1992). Methane and Methanol Utilizers. Boston, MA: Springer US. ISBN 1-4899-2338-1. {{cite book}}: |first1= has generic name (help)CS1 maint: multiple names: authors list (link) Gribble, volume editor, Gordon W. (2003). Natural production of organohalogen compounds. Berlin: Springer. ISBN 3-540-45293-1. {{cite book}}: |first1= has generic name (help)CS1 maint: multiple names: authors list (link)
Sources: en.wikipedia.org
=== Etymology === Obesity is from the Latin obesitas, which means "stout, fat, or plump". Ēsus is the past participle of edere (to eat), with ob (over) added to it. The Oxford English Dictionary documents its first usage in 1611 by Randle Cotgrave.
== Regimental commissions until First World War == 1. Garderegiment zu Fuß (1st Regiment of Foot Guards), Potsdam: Leutnant à la suite, from January 29, 1897; Oberleutnant, before 1908. à la suite, Grenadierregiment Konig Friedrich Wilhelm I. (2. Ostpreussisches) Nr. 3 à la suite, 2. Gardegrenadierlandwehrregiment (2nd Reserve Regiment of Grenadier Guards)
=== Endogenous fructose production === While the polyol pathway is traditionally associated with diabetic complications due to sorbitol accumulation, recent research has highlighted the metabolic role of the fructose produced. Under conditions of hyperglycemia, the activation of this pathway can lead to significant production of "endogenous fructose" in the liver and kidney. Review articles suggest that this endogenously produced fructose is metabolized by ketohexokinase, leading to ATP depletion, uric acid generation, and the stimulation of lipogenesis. This mechanism has been proposed as a contributing factor to the development of fatty liver and metabolic syndrome.
Sources: en.wikipedia.org
== Medical uses == Lercanidipine is used for the treatment of essential hypertension (high blood pressure). Lercanidipine seems to be a good agent in treating hypertensive patients who also have kidney issues.
== Epidemiology == The beta form of thalassemia is particularly prevalent among Mediterranean peoples, and this geographical association is responsible for its original name. Thalassemias resulted in 25,000 deaths in 2013, down from 36,000 deaths in 1990. In Europe, the highest concentrations of the disease are found in Greece, coastal regions in Turkey (particularly the Aegean Region such as İzmir, Balıkesir, Aydın, Muğla, and Mediterranean Region such as Antalya, Adana, Mersin), in southern Spain, in parts of Italy, particularly southern Italy. With the exception of the Balearics, the major Mediterranean Islands, such as Sicily, Sardinia, Malta, Corsica, Cyprus, and Crete are heavily affected. Other Mediterranean peoples, as well as those in the vicinity of the Mediterranean, also have high rates of thalassemia, including people from North Africa and West Asia. Far from the Mediterranean, South Asians are also affected, with the world's highest concentration of carriers (16–18% of the population) in the Maldives. The disease is also found in populations living in Africa, the Americas, and in Tharu people in the Terai region of Nepal and India. It is believed to account for much lower rates of malaria illnesses and deaths, accounting for the historic ability of Tharus to survive in areas with heavy malaria infestation while others could not. Thalassemias are particularly associated with people of Mediterranean origin, Arabs (especially Palestinians and people of Palestinian descent), and Asians.
== Activation and membrane transport == Free fatty acids cannot penetrate any biological membrane due to their negative charge. Free fatty acids must cross the cell membrane through specific transport proteins, such as the SLC27 family fatty acid transport protein. Once in the cytosol, the following processes bring fatty acids into the mitochondrial matrix so that beta-oxidation can take place.
Operation Silk Purse, for the Commander in Chief, U.S. European Command (USCINCEUR), based at RAF Mildenhall in the United Kingdom (callsign Seabell) Operation "Scope Light", for the Commander in Chief, U.S. Atlantic Command (CINCLANT), based at Langley AFB, VA Operation "Blue Eagle", for the Commander in Chief, U.S. Pacific Command (USCINCPAC), based at Hickam AFB, HI Operation "Nightwatch", which supported the President of the United States, and were based at Andrews AFB, Maryland. In the early 1970s the E-4A aircraft replaced the EC-135Js on this mission. The Eastern Auxiliary (EAST Aux) and Western Auxiliary (West Aux) Command Posts were also part of the WWABNCP ("wah-bin-cop") network and were capable of assuming responsibility for Looking Glass as the anchor. The West Aux 906th Air Refueling Squadron was based at Minot AFB, North Dakota, and moved to the 4th Airborne Command and Control Squadron at Ellsworth AFB, South Dakota in April 1970. The East Aux mission 301st Air Refueling Squadron was based at Lockbourne AFB, Ohio. In April 1970, the role moved to the 3rd Airborne Command & Control Squadron at Grissom AFB, Indiana. After 1975, East Aux was assumed from the Looking Glass backup ground alert aircraft launched from Offutt AFB. In June 1992, United States Strategic Command took over the Looking Glass mission from the Strategic Air Command, as SAC was disbanded and Strategic Command assumed the nuclear deterrence mission.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.